Ameritox

Archive for the ‘ Press Release ’ Category

Ameritox’s Ingenuity Health Announces Research Study from UCLA Center for Health Services and Society

November 15, 2016 / Mike Gottfried

Results to Focus on the Utility of Urine Drug Monitoring among Behavioral Health Patients

BALTIMORE, November 15, 2016 — Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians and a service of AmeritoxSM, today announced it has commissioned a research study by the UCLA Center for Health Services and Society that will help establish the first clinical guidelines for the use of urine drug monitoring among behavioral health patients who have been diagnosed with a serious mental illness. The research for the study has been completed, and the analysis is forthcoming.

“Using urine drug monitoring is still a very new concept in behavioral health, and this study will give us a solid understanding of how clinicians are utilizing it now, and how it’s helping those same clinicians in treating their patients,” said Ameritox Chief Medical Officer Thomas Smith, MD.

The UCLA Center for Health Services and Society was selected for their expertise in enhancing the health of communities; access to and quality of care; and qualitative research. All Center publications undergo a rigorous peer review process to verify the accuracy of findings and to gauge their relevance and utility to intended audiences.

The research findings will be announced by both Ameritox and the UCLA Center for Health Policy Research. Please visit http://hss.semel.ucla.edu for more information about this research institution.

About Ingenuity Health

As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness.

Visit the Ingenuity Health website at: www.ingenuityhealth.com
Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact:
Genevieve Rozansky
30 Point Strategies
Genevieve@30point.com
202-509-0794

Alexander Young, MD MSHS
UCLA Center for Health Services and Society
10920 Wilshire Blvd., Suite 300
Los Angeles, CA 90024
310-794-7219

Ameritox Study on ADHD Medication Behavior in Adolescents Reveals Which Drug is More Likely to be Misused or Diverted

November 2, 2016 / Mike Gottfried

Ameritox’s Ingenuity Health Committed to Finding Sub-trends That Will Help Doctors Better Treat and Protect Their Patients

BALTIMORE, Nov. 2, 2016 /PRNewswire/ — Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians and a service of AmeritoxSM, today released research showing that patients between the ages of 6 and 25 who are prescribed medication to treat Attention Deficit Hyperactivity Disorder (ADHD) were more likely to test negative for a prescribed amphetamine medication than a prescribed methylphenidate.

More than 35 percent of patients tested negative for a prescribed amphetamine, compared with just over 26 percent of those who tested negative for prescribed methylphenidate. The research outcomes are based on urine samples collected from patients over a 16-month period.

“Our research confirmed the ongoing problem of adolescents not taking their prescribed ADHD medication properly with almost 33 percent of the patients testing negative for the prescribed medication,” said Ameritox Chief Medical Officer Thomas Smith, MD. “Interestingly, the study also suggests that the amphetamine drugs are more likely to be misused or diverted than methylphenidate.”

“One hypothesis in the treating community is that amphetamine- a drug which is highly effective for ADHD – is also more likely to be diverted to the street or shared with friends,” Smith continued. “While our study does not provide proof that this is the case, it does support the hypothesis.”

“When we begin a study, we seek to either confirm or deny a broad trend within medical research, but we also want to dive down into sub-trends that will help the doctors we serve to better understand their patients, and protect them from dangerous behavior,” said Scott Walton, Ameritox CEO. “This research shows our commitment to isolating the troubling behavior that can lead to poor patient outcomes and potential human tragedy, and to providing clinicians the added knowledge to help prevent it.”

The Ameritox Medical Affairs team this week presented this research in the form of a medical poster titled “Medication Adherence in Pediatric and Young Adult Patients Prescribed ADHD Stimulant Medications” to the American Academy of Child and Adolescent Psychiatry conference, held in New York. For more information on this conference, please visit: http://www.aacap.org/annualmeeting/2016.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com Follow Ingenuity Health on Twitter: www.twitter.com/ameritox

About Ingenuity Health

As part of AmeritoxSM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness (SMI).

Visit the Ingenuity Health website at: www.ingenuityhealth.com Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

Contact:
Genevieve Rozansky
30 Point Strategies
131692@email4pr.com
202-509-0794

SOURCE Ameritox

Ameritox

Web Site: http://www.ameritox.com

Ameritox: Ingenuity Health Releases Updated Data Revealing Persistent Problem of Medication Non-adherence Among Those with Serious Mental Illness

October 26, 2016 / Mike Gottfried

Study Also Highlights Dangerous Trend of SMI Patients Misusing and Abusing Benzodiazepines and Non-prescribed Antipsychotic Drugs
 
BALTIMORE, October 26, 2016 — AmeritoxSM, a national leader in medication monitoring solutions, today announced updated research reaffirming the problem of medication non-adherence among patients prescribed antipsychotic drugs to treat diagnosed Serious Mental Illness (SMI). The study reveals that nearly 25 percent of patient samples tested negative for the prescribed medication.

“Medication non-adherence among those with SMI can create significant hardship. These patients have increased risk for substance use disorders and negative clinical outcomes such as an increased number of hospital visits and longer stays,” said Ameritox Chief Executive Officer Scott Walton.

“While our latest research unfortunately confirms a continuing trend, it also reveals a new worry for clinicians – misuse and abuse of benzodiazepines and non-prescribed antipsychotic drugs among those with SMI,” said Ameritox Chief Medical Officer Thomas Smith, MD.

The study showed that 7.3 percent of samples that tested negative for the prescribed antipsychotic and 5.3 percent of samples that tested positive for the prescribed antipsychotic also contained the presence of a benzodiazepine, such as brand names Xanax®, Valium®, or Ativan®. A non-prescribed antipsychotic medication was found in 6.7 percent of samples.

“Given the documented harmful effects of drug interactions among benzodiazepines and antipsychotics, misusing or abusing these drugs at the same time can be life-threatening,” Smith said.

Ameritox conducted its first behavioral health population study in the fall of 2014, with 7,700 patient samples comprising its universe of data. The updated research is based on more than 62,000 samples.

The Ameritox Medical Affairs team this week presented this research in the form of a medical poster titled “Urine Drug Monitoring in Patients on Prescribed Antipsychotic Medications” to the U.S. Psychiatric and Mental Health Congress, held in San Antonio, Texas. For more information on this conference, please visit: www.psychcongress.com.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Contact:
Genevieve Rozansky
30 Point Strategies
genevieve@30point.com
202-509-0794

UNITE holds Shoot Hoops Not Drugs event

June 24, 2016 / Mike Gottfried

So many life lessons can be learned from the game of basketball,” former University of Kentucky basketball player Jeff Sheppard said. “It’s the least I can do to spend some time with the kids in our communities and deliver a message about basketball but a message of hope as well about staying away from drugs and making the right decisions.”

Sheppard along with former UK Wildcat Jarrod Polson joined forces with Operation Unite for the 5th Annual Shoot Hoops Not Drugs event. Over 100 children from across the area came to the event to learn basketball fundamentals and an important message about drug abuse.

“Just the overall message of the camp is just trying to get kids away from the drug scene and how it’s been prevalent in the mountains. Anything to do to prevent that and help those kids and get them on a different path is something I like to do,” Polson said.

UNITE joined together with Ameritox, a company that “the nation’s leader in pain medication monitoring, offering laboratory services and practice management tools to help clinicians coordinate and optimize the care of chronic pain patients,” according to its website.

Ameritox’s director of communications, Lon Wagner, said, “We (Ameritox) wanted to sponsor this event. We’re involved in battling the prescription drug epidemic, and so is Operation Unite. Part of our mission, as we say, is to prevent human tragedy.”

“We want to instill in the kids a couple of things,” Wagner said. “Don’t do drugs that don’t belong to you. Secondly [this camp] is a good, healthy activity. Even if you never end up playing basketball, you’re out here, exercising, getting your heart rate up and doing something positive.”

Sheppard and Polson taught children of all ages the fundamentals of basketball, ranging from basic ball handling skills to defensive stances. This was the final Shoot Hoops Not Drugs camp that Operation UNITE held.

Operation UNITE will also be holding a week long leadership camp at the end of July at the University of Cumberlands.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Josh Silberberg
30 Point Strategies
(202) 304-1546
joshua@30point.com

Ameritox Partners for Third Year with Operation UNITE Youth Basketball Camps Focused on Drug Abuse Prevention

June 10, 2016 / Mike Gottfried

“Shoot Hoops, Not Drugs” summer basketball camps offer rural Kentucky students the necessary skills to help prevent drug misuse and abuse

BALTIMORE, MD. – June 10, 2016 — AmeritoxSM, a national leader in medication monitoring solutions, will sponsor for the third consecutive year a series of basketball camps organized by Kentucky-based Operation UNITE. The camps are headed by former University of Kentucky basketball stars who teach basketball skills that also incorporate anti-drug messages aimed at boosting students’ self-worth.

“By hosting these basketball camps for more than a decade, Operation UNITE has helped instill Eastern Kentucky youth with the self-esteem needed to steer clear of the prescription drug abuse that has devastated their community,” said Scott Walton, Ameritox CEO. “Ameritox is proud to sponsor these camps, because like Operation UNITE, we know that this epidemic can only be stopped by preventing the next generation from succumbing to opioid misuse and abuse.”

Operation UNITE was created by Kentucky Congressman Hal Rogers in 2003 to bring together government, law enforcement and businesses in fighting Kentucky’s rampant drug problems. The camps were created to foster strong deterrents for drug abuse in school-aged children.

Ameritox employees will provide support to Operation UNITE staff at the camps.
 
“We’re grateful to once again have Ameritox’s generous support, but we’re even more grateful that they continue to fight alongside us in the battle to prevent our kids from traveling down the frightening path of drug abuse,” said Nancy Hale, CEO of Operation UNITE.

The five free 2016 camps will be led by former University of Kentucky Final Four MVP Jeff Sheppard. All-SEC Academic Team member Jarrod Polson will join Sheppard for the last three camps. The dates and locations of the camps are:

  • Tuesday, June 14 – Warfield Middle School, Warfield, Martin County
  • Thursday, June 16 – Owsley County High School, Booneville
  • Monday, June 20 – Morgan County High School, West Liberty
  • Tuesday, June 21 – Rodney C. Woods Gym, Wayne County Schools Campus, Monticello
  • Thursday, June 23 – Knott County Sportsplex, 450 Kenny Champion Loop, Leburn

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

About Operation UNITE
Operation UNITE, which stands for Unlawful Narcotics Investigations, Treatment & Education, seeks to fight the drug epidemic by expanding drug awareness and education programs to keep people from using drugs; coordinating drug treatment and outreach programs for those who are already addicted; and operating regional undercover law enforcement task forces for interdiction and prosecution of those dealing drugs.

Visit the UNITE website at: www.operationunite.org

Ameritox Research Confirms Significant Spike in Potential Nonadherence to Opioid Medications

February 22, 2016 / Mike Gottfried

BALTIMORE, Feb. 22, 2016 — AmeritoxSM, a national leader in medication monitoring solutions, presented new research Friday showing a nearly 20-percent increase in the share of patient samples that do not contain the patient’s prescribed opioid medication. Attendees at the American Academy of Pain Medicine (AAPM) Annual Meeting, held in Palm Springs, California, learned that a full 43 percent of patient samples collected over a period of 31 months ending in July 2015 showed potential nonadherence. The 2012 Ameritox National Prescription Drug Report found that 35.9 percent of patient samples showed potential nonadherence.

Samples where a prescribed opioid is not detected raise serious concerns about patient care or the risk of drug diversion – intentional or accidental.

Based on samples collected from more than 447,000 patients between January 2013 and July 2015, the Ameritox data showed that potential nonadherence was greatest among those aged 10-19, at a rate of 62 percent. Though potential nonadherence declined in each decade after that, it remained significant even among those aged 60-69 (potential nonadherence, 39 percent) and those aged 70-79 (potential nonadherence, 37 percent).

“We understand that many patients find it difficult to have conversations with their doctor about their treatment,” said Ameritox Chief Medical Officer Dr. Tom Smith. “Medication monitoring results can help prompt doctor-patient discussions that lead to improved patient care, and also is an important tool in reducing misuse, abuse and diversion of prescription medication.”

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Josh Silberberg
30 Point Strategies
(202) 304-1546
joshua@30point.com

Ameritox Data on ADHD Stimulant Prescriptions Uncovers Significant Rates of Illicit Drug Use and Potential Nonadherence to Drug Regimen

January 18, 2016 / Mike Gottfried

WASHINGTON – January 18, 2016 – AmeritoxSM, a national leader in medication monitoring solutions, presented new research showing that in one out of three samples of patients prescribed stimulants to treat attention-deficit/hyperactivity (ADHD) disorder the prescribed drug was not detected. Members of Ameritox’s Medical Affairs team prepared the data for attendees at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting, held in Washington, where conference organizers highlighted the Ameritox report for attendees.

Based on samples collected from more than 4,000 patients between July 1, 2014 and June 30, 2015, the Ameritox data showed indications that potential nonadherence to prescription stimulants in the treatment of ADHD is associated with elevated rates of illicit drug use as well as non-medical use of opioids and benzodiazepines. In samples where the prescribed stimulant was not detected, THC was present more than 20 percent of the time. Nearly four in ten samples where the prescribed stimulant was not detected tested positive for some combination of a nonprescribed opioid, nonprescribed benzodiazepine, THC and/or cocaine.

In addition, patients being treated for ADHD with prescription stimulants showed high rates of potential nonadherence across all age groups. Patients over the age of 60 showed the lowest rates of potential nonadherence, with 24.4 percent of samples absent the prescribed drug. Patients between ages 20 and 29 had the highest rates of potential nonadherence, as more than 40 percent of all samples collected from patients in that age range tested negative for their prescribed stimulant.

“Even in the best case scenarios,” said Ameritox Chief Medical Officer Dr. Tom Smith, “the potential for diversion or illicit drug use is alarmingly high. The misuse, abuse and diversion of ADHD medications cannot be casually brushed aside when these results suggest that even when the prescribed ADHD medication is found there is a nearly one in four chance that the sample will also test positive for potentially dangerous substances.”

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Josh Silberberg
30 Point Strategies
202-304-1546
josh@30point.com

Ameritox Wins Award for Compliance Training

December 17, 2015 / Mike Gottfried

Respected human capital management firm recognizes value of Ameritox compliance program

BALTIMORE, Dec. 17, 2015 /PRNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions, today announced the “Ameritox STARK Shark Challenge,” a supplement to annual compliance training that focuses on interactions with potential clients, won a bronze medal as part of the 2015 Brandon Hall Group Excellence in Awards for Learning and Development, Talent Management, and Sales and Marketing.

Logo – http://photos.prnewswire.com/prnh/20151217/296848LOGO

“Ameritox’s compliance efforts do not amount to a box we simply check. Our focus ensures responsible expansion of our business, reinforces our mission to strengthen improve patient care and prevent human tragedy, and sets a high standard for our industry,” said Scott Walton, CEO of Ameritox.

Entries for the Brandon Hall Group Excellence Awards were evaluated by a panel of veteran, independent senior industry experts along with Brandon Hall Group senior analysts and executive leadership. The entries were judged based on their ability to fit the need, the design of the program, functionality and innovation.

The Ameritox STARK Shark Challenge was redesigned in 2014 with the help of GP Strategies, a sales and technical training consulting firm, to transform pages of flat text into an engaging scenario that invites participation, questions, and ultimately, deepens understanding of a critical component of the Ameritox compliance program.

“The high quality of work and commitment to driving business results among our award winners never fails to amaze me,” said Rachel Cooke, Chief Operating Officer of Brandon Hall Group and head of the awards program. “But the real winners of this award are Ameritox’s customers and clients because of the innovation and customer focus the company demonstrates.”

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse and diversion. As a trusted leader in medication monitoring, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ameritox Applauds Maryland Governor’s Heroin and Opioid Emergency Task Force for Recommending Statewide Use of Medication Monitoring

December 8, 2015 / Mike Gottfried

BALTIMORE, Dec. 8, 2015 /PRNewswire-USNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions, today applauded the Maryland Heroin and Opioid Emergency Task Force, chaired by Maryland Lieutenant Governor Boyd K. Rutherford, for recommending the use of prescription medication monitoring statewide in the Task Force’s final report to Governor Larry Hogan. This recommendation follows examples set by Kentucky, Indiana, Washington and Georgia of requiring some form of medication monitoring for those who are being prescribed opioids for the long-term.

Logo – http://photos.prnewswire.com/prnh/20151208/294145LOGO

“We’re very pleased these leaders clearly recognize that prevention is a crucial part of stopping the opioid epidemic, and medication monitoring remains a key facet of successful prevention,” said Todd Gardner, Chief Operating Officer of Ameritox. “Maryland is served well by the fact that the Task Force understands the importance of prescription medication monitoring as a critical tool in the fight to curb opioid misuse, abuse and diversion.”

The Task Force explains in its final report that medication monitoring “could lead to better health outcomes by detecting possible diversion of prescription opioids or the presence of non-prescribed or illicit drugs in urine samples.” The report cited clinical research from Ameritox, which found that 48 percent of patient samples from Maryland contained a drug that had not been prescribed by the doctor who ordered the drug screening. This percentage reflects the second worst rate in the country, according to Ameritox’s data.

A copy of the final report from the Maryland Heroin and Opioid Emergency Task Force can be found here.

Gardner will testify Wednesday before the Maryland Joint Legislative Committee on Opioid Disorders about how medication monitoring can improve patient outcomes, while preventing tragedy. Additionally, Ameritox’s service PRIUM, a chronic pain medical management company specializing in workers’ compensation, is currently collaborating with Maryland-based Chesapeake Employers Insurance Company on a pilot program. The aim is to identify specific cases of injured workers being prescribed significantly high dosages of opioids and to engage directly with their doctors to help create better patient outcomes. The full results of the program will be announced in the coming months.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring Solutions(SM), Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent human tragedy. Ameritox, headquartered in Baltimore, Md., has a national footprint and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ameritox Service PRIUM Announces Pilot Program With Chesapeake Employers Insurance Company to Improve Patient Outcomes for Workers’ Compensation Patients

November 24, 2015 / Mike Gottfried

BALTIMORE, Nov. 24, 2015 /PRNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions and its service PRIUM, a chronic pain medical management company specializing in workers’ compensation, today announced the creation of a pilot program with Maryland-based Chesapeake Employers Insurance Company to identify specific cases of injured workers being prescribed significantly high dosages of opioids and to engage directly with their doctors to help create better patient outcomes.

Logo – http://photos.prnewswire.com/prnh/20151124/290665LOGO

The pilot program is a direct response to the troubling rate of opioid misuse, abuse and diversion in Maryland, where Ameritox is headquartered. In 2014, Ameritox clinical data identified Maryland among the nation’s 10 worst states in two problem areas: “Non-prescribed drug found,” which translates to a prescription opioid not prescribed to the patient being detected in the collected urine sample, and “one or more illicit drugs found” in patients’ samples.

The goal of the pilot study is for PRIUM’s physician consultants to engage with the physicians treating injured workers to achieve a meaningful reduction in the patients’ morphine equivalent dosages (MED). Chesapeake is identifying patients and physicians for PRIUM. Independent clinical research has shown that gradually and responsibly decreasing an injured worker’s MED amount can lead to overall better health and a return to work.

“Chesapeake’s interest in this program reflects our focus on exploring innovative approaches to reducing the negative impact that opiate overuse and dependence is having on the lives of injured workers and their families,” said Dr. Stephen Fisher, Director of Health Services for Chesapeake.

“All of these cases so far raise significant alarm – each shows potentially excessive opioid prescribing and use,” said Michael Gavin, President of PRIUM. Gavin explains the extent of the problem: “For instance, most state regulations say that 60-100 MED per day is acceptable, but that anything over that greatly increases the risk of drug overdose. These cases all exceed 300 MED per day.”

Preliminary findings of the Ameritox/PRIUM/Chesapeake pilot program were discussed in testimony before the Maryland Inter-Agency Heroin and Opioid Coordinating Council. The two Maryland-based companies came together after discussions that began while providing input to the Heroin and Opioid Emergency Task Force, established by Governor Larry Hogan and headed by Lt. Gov. Boyd Rutherford.

“We’re proud to be working with Chesapeake to help prevent human tragedy and make patients’ lives better, and we’re especially thankful for the attention of leaders in Maryland state government toward fighting the opioid epidemic,” said Todd Gardner, Chief Operating Officer of Ameritox.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has a national footprint and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ameritox Advocate and Former DEA Special Agent to Lead Symposium on Preventing Prescription Opioid and Heroin Abuse in Local Community

October 28, 2015 / Mike Gottfried

BALTIMORE, Oct. 28, 2015 /PRNewswire/ — AmeritoxSM, a national leader in medication monitoring solutions, today announced that Richard A. Tucker, retired Assistant Special Agent in Charge with the Drug Enforcement Administration (DEA), will lead a symposium to empower Cobb County Georgia community members to help prevent prescription opioid and heroin abuse among their loved ones, friends and neighbors.

Logo – http://photos.prnewswire.com/prnh/20151028/281444LOGO

The 5th Annual “Becoming Your Own Advocate” symposium on October 29th is organized by the Davis Direction Foundation and sponsored by WellStar Health Systems, both of Cobb County. Tucker offers symposium attendees a lifetime of experience in preventing and fighting opioid misuse, abuse, and diversion, having served 10 years as a police officer in Cobb County at the beginning of his career, and 25 years with the DEA on assignments in Atlanta, Denver, El Paso, Texas, Los Angeles and Thailand to investigate global drug trafficking operations. He also served in Washington, D.C. as the chief of the DEA’s International Intelligence Program.

The Davis Direction Foundation was created in memoriam of Davis Owen, who to combat stress and anxiety developed a well-hidden prescription painkiller addiction as a teenager. The prescriptions he stole out of his family’s medicine cabinet eventually led Davis to heroin abuse — and to his death in March 2014 of a heroin overdose. The Davis Direction Foundation works one-on-one with individuals and their doctors and family members to tear down the outdated stigmas of opiate addicts and to restructure the long process of drug rehabilitation to recognize and escalate opiate addiction as a severe and all-too-common

“We’re thrilled to have Rick leading this year’s symposium as a Cobb County native, and as someone who has seen firsthand all over the world the fight we’re all fighting,” said Missy Owen, Executive Director of the Davis Direction foundation. “Only by working together as a community – which includes doctors, patients, family members, and law enforcement – are we going to prevent the prescription opioid and heroin abuse that has claimed the lives of too many loved ones, including our son, Davis.”

Cobb County has identified a significant problem with opioid misuse, abuse and diversion: In 2013, a large percentage of the cases handled by a local law enforcement narcotics unit involved prescription painkillers and other drugs.

“With every additional person who gets educated about the triggers and warning signs of prescription opioid and heroin abuse, our chances to prevent more tragedies goes up,” said Tucker. “This is an important gathering that could lead to many more lives being saved.”

Attending “Becoming Your Own Advocate” will offer a powerful and educational understanding of the epidemic in Cobb County. The symposium will take place at 7 p.m. at Marietta First United Methodist Church, 56 Whitlock Ave. SW, in Marietta, GA.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has a national footprint and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742

Genevieve Rozansky
202-509-0794

Ingenuity Health Releases First Research Report On Potential Medication Non-Adherence and Misuse of Opioids and Illicit Drugs among the Seriously Mentally Ill

September 8, 2015 / Mike Gottfried

Research based on urine drug testing focused on exposing the problems associated with
medication non-adherence in those with SMI and how medication monitoring can help

BALTIMORE – Sept. 8 – Ingenuity Health, a service of Ameritox, Ltd., and a leading provider of medication monitoring solutions to behavioral health clinicians, today released its first-ever research report that examines the extent of potential patient non-adherence to antipsychotic medications used to treat serious mental illness (SMI). The report details the harmful effects of non-adherence for patients and society along with the equally pernicious problem of misuse of prescription painkillers and abuse of illicit drugs in patients with SMI.

Based on nearly 23,000 patient samples collected through urine drug monitoring and tested for
the presence of a prescribed antipsychotic, 24.8 percent of samples did not contain the prescribed antipsychotic, 33 percent contained a non-prescribed drug and 19.7 percent contained an illicit drug. Marijuana and non-prescribed benzodiazepines (such as Valium or Xanax) were the most commonly detected illicit drugs and non-prescribed drugs.

“Medication non-adherence, along with the practice of misusing and abusing opioids and the
abuse of illicit drugs, occur too often among people with serious mental illnesses, and pose
serious risks to the health and welfare of these patients, and to those around them,” said Jerry Vaccaro, MD, President of Ingenuity Health. “With these obstacles to long-term health, the more additional insight into adherence that we can provide, the better clinicians can treat and manage their patients and prevent tragedy.”

“We’re publishing these internal results because the consequences of those with serious mentalillness going untreated are enormous for both patients and the communities they live in,” said Scott Walton, CEO of Ameritox. “We also hope that these facts will help public officials, health care workers, community groups, educators and media use this data to address the issues that mental illness creates for patients and for society.”

About Ingenuity Health

As a service of Ameritox℠, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with SMI.

Visit the Ingenuity Health website at: www.ingenuityhealth.com

Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national
epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring Solutions℠, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com

Follow Ameritox on Twitter: www.twitter.com/ameritox

Lon Wagner, Ameritox
Office: 336-387-7742
lon.wagner@ameritox.com

Genevieve Rozansky, 30 Point Strategies
Office: 202-509-0794
genevieve@30point.com

Ingenuity Health Study Reveals Potential Non-Adherence to Antipsychotic Medications Differs Based on Diagnosis

June 24, 2015 / Mike Gottfried

Will Present Clinical Research to Psychopharmacology Community


BALTIMORE – June 24, 2015 – Ameritox’s Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians, today announced new clinical research based on urine drug monitoring samples that revealed that participants who suffer from bipolar disorder and severe depression are more likely to be non-adherent to their prescribed antipsychotic medication than those who suffer from schizophrenia. These results differ from recent literature on non-adherence in those with serious mental illness (SMI).

Medication nonadherence can result in significant barriers to the long-term health of those with SMI.

“This research challenges current notions about medication adherence among those with bipolar disorder and severe depression, but it remains clear that non-adherence is the single greatest threat to long-term health for those who suffer from SMI,” said Tom Smith, M.D., Chief Medical Officer for Ingenuity Health and Ameritox.

Ingenuity Health medical scientists, along with research contributor Dr. Robert Millet, Assistant Medical Director of Carolina Behavioral Care in Raleigh, NC, will present the research in a medical poster titled “Adherence to Treatment With Antipsychotic Medications Among Patients With Schizophrenia, Major Depressive Disorder, or Bipolar Disorder” today at the annual meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, Fla.

“Simply put, this study shows that we need more vigilance of medications among the seriously mentally ill, especially considering that medication monitoring is the easiest way to improve patient outcomes,” said Dr. Millet. “Although it’s widely accepted that patients with schizophrenia would benefit from medication monitoring, this dataset suggests that patients with bipolar disorder and depression should also be monitored.”

Additionally, Ingenuity Health will present at the ASCP annual meeting a medical poster titled “Evaluation of Cytochrome P450 Phenotypes and Potential Implications in the Treatment of Serious Mental Illness.”

For more information about ASCP and its annual meeting, visit https://www.ascpp.org.

About Ingenuity Health
As part of Ameritox, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness (SMI).

Visit the Ingenuity Health website at: www.ingenuityhealth.com
Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Genevieve Rozansky
202-509-0794
genevieve@30point.com

Millennium Health to Pay $8.6 Million for Infringing on Ameritox-licensed Patent

April 22, 2015 / Steve Denker

Federal Jury Unanimously Finds that Millennium Health (formerly Millennium Laboratories) Infringed Underlying Patent of Ameritox’s Rx Guardian CD®

BALTIMORE – April 22, 2015 — A federal jury has unanimously found Millennium Health (formerly Millennium Laboratories) to have infringed U.S. Patent No. 7,585,680 (the “‘680 Patent”). The jury awarded Ameritox $8.6 million in damages.

The ‘680 Patent is owned by the Marshfield Clinic, a non-profit healthcare system of hospitals and community care centers in Wisconsin, and exclusively licensed to Ameritox. The jury’s decision upheld the validity of the patent and, along with an earlier court decision, resulted in Millennium’s removal of the infringing features of the RADAR® Report.

Millennium began infringing on the patent by unveiling its RADAR Report with graphed results three weeks after Ameritox launched its Rx Guardian CD® medication monitoring program in May 2011. Millennium continued infringing on the patent by using its RADAR Report with graphed results into 2015.

Ameritox’s Rx Guardian CD service compares a patient’s normalized urine drug monitoring results to a database of patients clinically assessed as adherent. Ameritox’s INSIGHT report displays those results graphically on a bell curve.

Millennium’s RADAR Report compares a patient’s normalized urine drug monitoring results to a database of patients prescribed the same medication – though those patients have not been clinically assessed as adherent. Millennium’s RADAR report displayed those results graphically on a bell curve.

The Chief Judge of the Western District of Wisconsin, William M. Conley, addressed this difference in a pre-trial Summary Judgment Order: “While … shortcomings in the data used in Millennium’s RADAR Report may well make for an inferior product, they do not render the product non-infringing.”

The ‘680 patent covers Ameritox’s Rx Guardian CD service and reports. The Rx Guardian CD display is designed to improve treatment outcomes by giving clinicians more insight into whether a patient may be taking prescribed medications correctly.

“Rx Guardian CD is a highly differentiated offering that brings unique value and insights to our customers,” said Ameritox CEO Scott Walton.  “We are proud that we are the scientific leader in the industry and pleased that the court decision has served to validate that fact.”

After the ‘680 Patent was issued by the U.S. Patent and Trademark Office, Millennium twice sought reexamination of it in an effort to have it invalidated.  On both occasions, the Patent Office affirmed its previous decision on patentability.

This is the second jury within a year that has ruled in favor of Ameritox against Millennium. In June 2014, a judge and jury in the Middle District Court of Florida, found Millennium in violation of the federal Anti-Kickback Statute and Stark laws for offering doctors free Point-of-Care Testing cups, which was found to constitute illegal inducements for business.  In that case, Ameritox was awarded more than $11 million in damages.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Genevieve Rozansky
202-509-0794
genevieve@30point.com

Ameritox and Ingenuity Health Expand Effort to Help Assess Medication Adherence in those with Serious Mental Illness

October 20, 2014 / Steve Denker

Ameritox’s Ingenuity Health introduces method to help assess medication adherence in patients prescribed Risperdal®

BALTIMORE, MD. – Oct. 20, 2014 — Ameritox, the nation’s leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug risperidone (tradename, Risperdal®). This new method marks a critical step toward establishing a comprehensive reference database for commonly prescribed antipsychotic medications, providing behavioral health clinicians help in addressing the acute problem of medication non-adherence in those with serious mental illness.
Ameritox’s Ingenuity Health service conducted research that allows it to provide additional information about whether a patient may be taking risperidone in accordance with his or her prescribed treatment plan. By comparing normalized urine drug results against the results of patients clinically assessed as adherent, behavioral health centers and medical professionals will have more information as they manage and treat patients prescribed risperidone.
Risperidone now joins Abilify®, the nation’s top-selling medication, and Seroquel XR®, a branded form of quetiapine, as medications for which Ingenuity Health has established a reference range for better assessing medication adherence. In addition, Ingenuity Health offers detection tests for other drugs commonly prescribed to treat schizophrenia and bipolar disorder, including Clozaril®, Geodon®, Haldol®, Invega®, Zyprexa® and Latuda®.
“One of the greatest barriers to helping those with serious mental illness has long been a lack of insight into whether a person is taking the prescribed medication,” said Mike DeGeorge, Director of Medical Affairs for Ameritox and Ingenuity Health. “This method helps address the problem that behavioral health clinicians face with half of their patients: medication non-adherence.”

This behavioral health-oriented database will expand Ameritox’s exclusive Rx Guardian CDSM, which goes beyond traditional data gathering to provide analysis that can help clinicians address the growing problem of pain medication misuse, abuse and diversion.
Additional research is underway to develop similar reference ranges for other commonly prescribed antipsychotics.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox
Watch Ameritox on YouTube: www.youtube.com/ameritox

Contacts:
Lon Wagner, Ameritox
Office: 336-387-7742
lon.wagner@ameritox.com

Genevieve Rozansky, 30 Point Strategies
Office: 202-509-0794
genevieve@30point.com

Ameritox Appoints New Chief Medical Officer

October 16, 2014 / Steve Denker

Brings 25 years of clinical and leadership experience to Ameritox brands

BALTIMORE – October 16, 2014 — AmeritoxSM, the nation’s leader in medication monitoring solutions, today announced the appointment of Thomas Smith, M.D., as Chief Medical Officer. In this role, Smith will lead a field-based team offering scientific resources for healthcare providers, patients and managed care plans.

Smith has held leadership positions at a variety of healthcare companies that have provided him with experiences that will benefit both the pain and behavioral health sides of Ameritox’s business. He most recently served as CMO for Mallinckrodt Pharmaceuticals, where he helped the company serve millions of patients around the world with effective and safe medications while helping to quickly grow the company’s market capitalization from $2 billion to $8 billion. He has also held clinical leadership roles at Abbott Laboratories, Teva Pharmaceuticals, Kendle International, Akros Pharma and Genzyme. In addition to vast expertise in Medical Affairs, Smith has led clinical development programs across all phases for the Food and Drug Administration and European Medicines Agency registration in a broad range of therapeutic areas. He also brings critical knowledge of working face-to-face with patients to Ameritox, having practiced family medicine for 12 years before moving to the clinical research side.

“With his well-rounded experience, Tom will greatly help us continue to advance our mission of improving the quality of patient care and preventing human tragedy. We’re proud to have him aboard,” said Scott Walton, CEO of Ameritox.

“Working for Ameritox, I’ll be able to go home each night knowing that we’ve helped provide information to physicians and healthcare workers to help ensure that patients are being effectively treated and are using their prescription drugs appropriately. That’s some real peace of mind,” said Smith.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox
Watch Ameritox on YouTube: www.youtube.com/ameritox

Contacts:
Lon Wagner, Ameritox
Office: 336-387-7742
lon.wagner@ameritox.com

Genevieve Rozansky, 30 Point Strategies
Office: 202-509-0794
genevieve@30point.com

Ameritox Research Report Reveals Pain Patients’ Role in Current Heroin Epidemic

September 2, 2014 / Steve Denker

Report examines deadly trends that created latest heroin scourge; Research to be presented at National PAIN Week conference September 2-6, 2014

BALTIMORE, MD. – Sept. 2, 2014 — AmeritoxSM, the nation’s leader in medication monitoring solutions, today released, “A Deadly Trend: Prescription Drugs to Heroin,” a research report that provides concrete evidence linking prescription drug abuse to heroin abuse, and examines deadly trends that have created a unique heroin epidemic. The full can be found here.

The report is based on data collected from urine drug testing of patients prescribed opioids. It examines five trends that distinguish the heroin abuse currently ravaging communities across the U.S. from the heroin scourges of the past. Among the key findings in the report:

  • Frequently, other illicit drugs and prescription drugs are combined with heroin use: 20 percent of heroin-positive samples also tested positive for a non-prescribed sedative hypnotic, such as Xanax or Valium, and 19 percent tested positive for cocaine.
  • Bouncing between drugs is common: Patients who tested positive for heroin did not test positive for their prescribed opioid 56 percent of the time.

“Ameritox is committed to preventing the human tragedy that too often results from prescription painkiller and heroin abuse,” said CEO Scott Walton. “”We hope that this research and report will serve as a resource for clinicians and others who share that goal.”

The data in the report was pulled from approximately 170,000 chronic pain patient samples tested by Ameritox for heroin over a two-year period. The research is being presented during the National PAIN Week conference in Las Vegas, Nevada this week.

Members of Ameritox’s Medical Affairs team will also present in-depth research with a medical poster entitled, “Heroin Use Among Pain Patients Prescribed Opioids.” A second research effort examines prescribing habits to explore trends in morphine equivalent dosing.

PRIUM’s New TaperRx Helps Physicians Wean Chronic Pain Patients from Complex Drug Regimens

August 18, 2014 / Steve Denker

ORLANDO, Fla.–(BUSINESS WIRE)–PRIUM, a medical intervention company specializing in reducing the inappropriate use of prescription drugs, announced its ground-breaking TaperRx service at the Workers’ Compensation Institute’s Educational Conference today.

“TaperRx provides physicians a ‘roadmap’ to assist them in reducing or eliminating the numerous prescription drugs in multiple classifications that chronic pain patients typically take”

“TaperRx provides physicians a ‘roadmap’ to assist them in reducing or eliminating the numerous prescription drugs in multiple classifications that chronic pain patients typically take,” said PRIUM Senior Vice President Mark Pew.

These drugs often include opioids, non-steroidal anti-inflammatories, benzodiazepines, muscle relaxants, and/or anti-depressants. Weaning patients off a mix of drug classifications is complicated because different drugs require different tapering protocols. Physicians need to decide which drugs to taper first, how to reduce their dosage, and what milestones to meet before moving to the next step.

PRIUM’s white paper, “An Analysis of Drug Therapy Tapering Guidelines” showed that no clinical guidelines address how to wean patients from multiple drugs in multiple classifications. The white paper is available at http://www.prium.com/resources/thought-leadership. TaperRx was developed to help provide clinical clarity to that process.

Using the best available science, PRIUM’s pharmacological and medical experts developed and oversee TaperRx, which delivers a detailed tapering roadmap customized to the patient’s unique drug regimen, physiological and psychosocial circumstances. TaperRx suggests a personalized tapering strategy with step-by-step recommendations, providing a clinical rationale for each.

“This is the healthcare industry’s first service to aggregate the best tapering evidence available to affect change in a complex drug regimen,” Pew said. “TaperRx augments the physician’s expertise, enables accountability and facilitates communication among the physician, patient and payer throughout the weaning process.”

Ameritox and Ingenuity Health Building Comprehensive Reference Database to Help Assess Medication Adherence in those with Serious Mental Illness

August 14, 2014 / Steve Denker

BALTIMORE, Aug. 14, 2014 /PRNewswire/ — AmeritoxSM, the nation’s leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug Seroquel XR, one of the 40 best-selling medications in the U.S. This new method marks a critical step toward building a comprehensive reference database, providing behavioral health clinicians help in addressing the acute problem of medication non-adherence in those with serious mental illness.

Ameritox’s Ingenuity Health service conducted research that allows it to provide additional information about whether a patient may be taking Seroquel XR correctly. By comparing normalized urine drug results against the results of patients clinically assessed as adherent, behavioral health centers and medical professionals will have more information as they manage and treat patients prescribed Seroquel XR.

“The singular problem of a lack of insight into whether a person is taking the medication prescribed has long been a barrier to helping those with serious mental illness,” said Mike DeGeorge, Director of Medical Affairs for Ameritox and Ingenuity Health. “This method helps address the problem that behavioral health clinicians face with 50 percent of their patients: medication non-adherence.”

Seroquel XR, a branded form of quetiapine, is the second antipsychotic medication for which Ingenuity Health has established a reference range for better assessing medication adherence. In March, Ingenuity Health introduced a reference range for Abilify, the nation’s top-selling medication.

In developing these reference ranges, Ingenuity Health is building a database for comparing a patient’s urine drug test results with those of a group of patients clinically assessed as adherent and taking the same medication. This database will expand Ameritox’s exclusive Rx Guardian CDSM, which goes beyond traditional data gathering to provide analysis that can help clinicians address the growing problem of pain medication misuse, abuse and diversion.

Additional research is underway to develop similar reference ranges for other commonly prescribed antipsychotics.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation’s trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Director of Medical Affairs: Ingenuity Health Database and Reference Ranges May Help Clinicians Better Treat Those with Serious Mental Illness

August 13, 2014 / Steve Denker

Director of Medical Affairs: Ingenuity Health Database and Reference Ranges May Help Clinicians Better Treat Those with Serious Mental Illness

Michael DeGeorge, PharmD, director of medical affairs for Ameritox and Ingenuity Health, discusses the launch of a method to help physicians assess medication adherence in behavioral health patients prescribed the antipsychotic drug Seroquel XR, one of the 40 best-selling medications in the U.S. In the Q&A below, DeGeorge explains how this method is the critical next step in building a comprehensive reference database of those with serious mental illness (SMI) who are clinically assessed as adherent to their prescribed antipsychotic, and the impact of this database.

What hurdles do clinicians face in treating those with SMI?

Studies show that about 50 percent of patients with serious mental illness don’t take their prescribed medication correctly, if at all. This creates one of the biggest barriers to long-term health for those with SMI, as medication non-adherence often leads to medical and societal problems, including hospitalizations, ER visits, and violent behavior. Medication monitoring can provide doctors and other specialists with objective information when assessing patients, positioning them to make more informed treatment decisions. A routine evaluation of medication use with a urine drug screen is recommended by leading national behavioral health associations, including the American Psychiatric Association.

What exactly did Ingenuity Health develop with regard to Seroquel XR? What effect will it have?

Ameritox’s Ingenuity Health conducted research that provides additional information to a physician about whether a patient may be taking Seroquel XR as prescribed. By comparing normalized urine drug monitoring results against this reference database of patients clinically assessed as adherent, clinicians will have more information as they assess, manage and treat patients prescribed Seroquel XR.

Ameritox developed a similar reference range for Abilify earlier this year. Why was Seroquel chosen as the next medication for which to develop a reference range?

Abilify is the top-selling medication in the U.S., and very widely prescribed, and Seroquel has a similar profile: It’s one of the 40 best-selling medications, and is a popular prescription for treating schizophrenia and other disorders.

How does the Seroquel reference range fit in to the reference database of behavioral health medication adherence?

Seroquel is one of eight antipsychotic medications Ingenuity Health currently offers testing for. The reference range curve is based on results from patients in a controlled study.

How can the reference database help clinicians?

The database can help clinicians in treating their patients by providing them with additional information to help address the acute problem of medication non-adherence in those with serious mental illness (SMI). This additional information can help physicians improve the quality of patient care and help the practitioner assess patients in making treatment decisions.

This reference range, along with one for Abilify that was launched earlier this year, adds to the line of prescription medication reference ranges in the Rx Guardian CD databases that helps physicians assess medication adherence.